SCI & TECH● LOW1h ago · Sep 8, 2026, 1:27 PM
Inhibrx cancer therapy outperforms Merck’s Keytruda in mid-stage trial
Seeking Alpha Tech · global
A cancer therapy developed by Inhibrx has reportedly shown superior performance to Merck's Keytruda in a mid-stage clinical trial. This indicates a potential advancement in cancer treatment.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Sci & Tech
SCI & TECH28m agoClosed nuclear fuel recycling can pave way for thorium-based energy: ScientistThe HinduSCI & TECH49m agoSpoiler alert: AI in cinema 'just a tool, won’t replace actors and human beings'France 24 [en]SCI & TECH55m agoDubai launches Agentic AI training drive for 14,000 businessesEuroNews [en]SCI & TECH56m agoBengaluru South Corporation deploys AI cameras to track potholes, garbage dumping, and encroachmentsThe Hindu